Future Cardia Takes a Huge Leap Forward

If you needed a sign to take advantage of Future Cardia’s recently extended Regulation Crowdfunding round on StartEngine, this might just be it.

The medtech leader is still early in its quest to disrupt a $5 billion market, but it just took a massive leap forward to that end. Yesterday Future Cardia announced the first successful in-human implants of its tiny insertable cardiac monitor device into nine patients, all of whom suffer from cardiac conditions.

“Imagine being healthy all around, except one aspect of your heart that depletes you and limits your daily life physically and psychologically,” wrote Future Cardia Founder and CEO Jaeson Bang in an update to investors. “That’s what our patients are experiencing all day, every day.”

The patients will have their cardiac condition remotely monitored around the clock by Future Cardia’s AI technology for the next two years. Their physicians will also be provided with actionable insights to more effectively manage and treat them along the way.

Recall I when I last highlighted Future Cardia’s story a few weeks ago, the deadline to invest in its Reg. CF offering on StartEngine had just been extended through Jan. 17, 2024. As of this writing, the company has raised just under $2 million through the round from 1,488 investors at a roughly $40 million valuation.

Future Cardia is still chasing an estimated $5 billion market in monitoring for the early signs of cardiac arrhythmia and heart failure. And it still claims its device can reduce hospitalizations by a significant margin, savings billions per year in healthcare costs.

If all goes well with these early patients over the next two years as Future Cardia continues along its path toward commercialization, investors who participate in these early crowdfunding rounds should be more than pleased with their decision.

To learn more about Future Cardia’s technology, team, and vision, you can visit its StartEngine offering page here.